RetaMaps

Avante Medical Center

Avante Medical Center · 915 West Northern Lights Boulevard · Anchorage, AK 99503

4.9· 821 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Avante Medical Center is a primary care practice in Anchorage, Alaska, serving families with general medical care, lab panels, hormone testing and thyroid testing, per its website, which dates the practice to 2004. The site lists clinicians including Bethany Buchanan, DNP, John H. Bocachica, MD, and Kelly Cerutti, APRN, and telehealth is available. On Google it holds a 4.9-star rating across 821 reviews dating back to 2017, 72 of them in the past year, with reviewers most often mentioning knowledge, the staff and a caring manner. The site doesn't name weight-management services, so ask directly whether any are offered.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.9
Google rating · 821 reviews
72
reviews in the past year (avg ★ 4.9)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-08-26. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.9 across 821 Google reviews. Of the 100 reviews we analyzed, 98 (98%) are positive (4–5★) and 2 (2%) are negative (1–2★).

What patients like

  • Knowledgeable, professional providers23 reviews
  • Friendly, helpful staff21 reviews
  • Feeling listened to19 reviews
  • Easy scheduling and communication5 reviews

Common complaints

Very few complaints — only 2 negative reviews, with no recurring theme.

5★
98
4★
0
3★
0
2★
0
1★
2

Most recent Google reviews

Sasha P.★★★★★2026-08-26

Avante is fabulous! Their staff are friendly and professional from the front desk staff to the technicians to the healthcare providers. I was a little nervous when my provider moved here, but I had noting to worry about. The location is incredibly convenient.

Joe H.★★★★★2026-08-25

Great

Jose A.★★★★★2026-08-25

This medical center is so efficient, the staff is so friendly, professional and always happy to see you. They have helped me keep my health in great shape for years. Thank you Rene B.

Matt D.★★★★★2026-08-18

Excellent service. Super friendly staff. Always helpful.

Ashley F.★★★★★2026-08-13

Very welcoming front desk folks. I felt heard by the practitioner and excited to take this new route for my healthcare

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Anchorage

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs